FindTrial
Sign In

Phase3 study of T-1220 in the patients with bacterial infectious disease-Open label, multi-center study-

Phase3 study of T-1220 in the patients with bacterial infectious disease-Open label, multi-center study-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221672
Enrollment
Unknown
Registered
2011-12-14
Start date
2011-12-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Acute bronchitis, Pneumonia, Lung abscess, Pyothorax, Secondarinfection of chronic respiratory disease, Cystitis, Pyelonephritis, Cholecystitis, Cholangitis, Bartholinitis, Intrauterine infection, Uterine adnexitis, Parametritis, Purulent meningitisy

Interventions

investigational material(s) Generic name etc : T-1220 INN of investigational material : Piperacillin Sodium Therapeutic category code : 613 Antibiotic preparations acting mainly on gram-positive, gram

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Sex:male or female (2)Age: 20 years and older for adult and 28 days to 16 years old (inclusive) for child (3)Outpatient or inpatient: inpatient (4)Presence of definite symptom/findings of infectious disease (5)Others

Exclusion criteria

Exclusion criteria: (1)Medical history of allergy to any beta-lactam antibacterial agents. (2)Patient with infectious mononucleosis. (3)Pregnant females, females wishing to become pregnant or being possibly pregnant, and lactating females. (4)Others.

Design outcomes

Primary

MeasureTime frame
Efficacy and safety Same as above—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026